Status:
UNKNOWN
Predictors of Disease Severity in COVID-19 Patients
Lead Sponsor:
Zeljko Mijailovic
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
The primary goal of the VIRIONUM project is to analyze the association of clinical, socio-demographic characteristics of patients and their genetic polymorphism, inflammatory and other biochemical mar...
Detailed Description
Background: Severe acute respiratory syndrome 2 (SARS-CoV-2) is etiological agent of heterogeneous corona-virus disease 19 (COVID-19), which clinical condition range from asymptomatic or mild to criti...
Eligibility Criteria
Inclusion
- Adult age, 18 years old or more
- Male or female
- Hospitalization for COVID-19 after confirmation by SARS-CoV-2 rapid antigen test or RT-PCR
- Voluntary written consent of the subject to participate
Exclusion
- Pregnant and breastfeeding women
- Fatal outcome during the first 24 hours of hospitalization
- Inability to collect the necessary study data
- Declining of the subject to voluntary participate in the study
Key Trial Info
Start Date :
April 4 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2023
Estimated Enrollment :
1019 Patients enrolled
Trial Details
Trial ID
NCT04887142
Start Date
April 4 2020
End Date
May 1 2023
Last Update
May 14 2021
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Spitali Amerikan
Tirana, Albania
2
General Hospital "Prim. dr. Abdulah Nakaš"
Sarajevo, Bosnia and Herzegovina
3
KBC Rijeka, University of Rijeka
Rijeka, Croatia
4
University of Montenegro, Faculty of Medicine
Podgorica, Montenegro